Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Hosseini A. et al, (2025), Nature
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential
Derré L. et al, (2023), Journal for ImmunoTherapy of Cancer, 11, e008020 - e008020
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R. et al, (2023), Cancers, 15
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I. et al, (2022), European urology open science, 45, 55 - 58
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S. et al, (2022), Journal for immunotherapy of cancer, 10
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S. et al, (2022), European urology focus, 8, 748 - 751
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S. et al, (2021), European urology open science, 34, 79 - 82
Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T-cell responses to acute and chronic viral infection.
Aparicio-Domingo P. et al, (2021), European journal of immunology, 51, 76 - 90